Opportunity Information: Apply for TI 10 001
Apply for TI 10 001
- The Substance Abuse Mental Health Services Adminis. in the health sector is offering a public funding opportunity titled "Cooperative Agreement for the Physician Clinical Support System for the Treatment of Substance Use Disorders" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243 Substance Abuse and Mental Health ServicesProjects of Regional and National Significance.
- This funding opportunity was created on Jul 1, 2009 and posted on Jul 1, 2009.
- Applicants must submit their applications by Sep 17, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility is limited to the national professional medical organizations authorized by the Drug Addiction Treatment Act of 2000 (DATA) to carry out the training of physicians desiring to prescribe and/or dispense FDA approved buprenorphine products for the treatment of addictive disorders. These are the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association. Any of these entities may apply individually they may also apply as a consortium comprised of all or several of the eligible organizations. If a consortium is formed for this purpose, a single organization in the consortium must be the legal applicant, the recipient of the award, and the entity legally responsible for satisfying the grant requirements. If a consortium submits an application, the application must include a written agreement outlining the roles and responsibilities of each participating national professional medical organization. This agreement must be signed by an authorized official of each member of the consortium and attached to the application in Attachment 4 of the RFA, Roles and Responsibilities of Participating National Professional Medical Organizations.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The FY 2010 Cooperative Agreement for the Physician Clinical Support System for the Treatment of Substance Use Disorders (PCSS) is a SAMHSA Center for Substance Abuse Treatment funding opportunity aimed at strengthening a national clinical support network that helps physicians treat opioid dependence using FDA-approved buprenorphine products. The program’s central goal is to enhance and further develop the existing DATA Physician Clinical Support System so that more clinicians, especially those who do not specialize in addiction medicine, can confidently and competently provide office-based treatment for patients dependent on heroin or prescription opioids. In practice, this means building on a functioning national infrastructure that already includes a large mentoring pool (over 70 mentors), five clinical experts, and a medical director, and then expanding and refining that capacity to reach more prescribers and improve the consistency and quality of care.
The opportunity is structured as a cooperative agreement, which typically indicates substantial federal involvement during the project period rather than a hands-off grant. It sits within SAMHSA’s broader “infrastructure” portfolio, meaning the focus is not simply on delivering direct patient services, but on building durable systems that make effective prevention and treatment services easier to deliver and sustain over time. Applicants are expected to lay out a clear logic connecting the needs in the field (for example, clinicians lacking experience with opioid dependence treatment), the infrastructure strategy proposed (such as mentoring models, clinical consultation, and expert guidance), and the resulting increase in system capacity that ultimately supports better, more sustainable treatment services nationwide.
PCSS is designed primarily for clinicians who encounter opioid-dependent patients but may be less familiar with addiction treatment than dedicated addiction specialists. The target audience explicitly includes primary care physicians, pain specialists, psychiatrists, and other non-addiction medical practitioners. At the same time, addiction specialists are not excluded; they are encouraged to participate either as learners within the system or as mentors who support other physicians seeking to provide buprenorphine-based treatment. The overall intent is to widen the circle of competent prescribers and improve clinical decision-making through ready access to mentorship and expert consultation, thereby supporting implementation of office-based opioid treatment as envisioned under federal law.
Eligibility is intentionally narrow and tied to the Drug Addiction Treatment Act of 2000 (DATA), as amended. Only the national professional medical organizations authorized under DATA to conduct training for physicians seeking to prescribe and/or dispense buprenorphine for opioid addiction may apply. The eligible organizations listed are the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association. Applications may be submitted by a single eligible organization or by a consortium of multiple eligible organizations. If a consortium applies, one organization must serve as the legal applicant and be responsible for the award and compliance, and the application must include a signed written agreement detailing the roles and responsibilities of each participating organization.
Funding details reflect a single national award: SAMHSA anticipated making one award with an estimated total funding amount of $500,000, with an award ceiling of $500,000 and no stated minimum (award floor $0). There is no cost sharing or matching requirement. The opportunity was posted July 1, 2009, with an application deadline of September 17, 2009, and an archive date of October 17, 2009. The funding activity category is Health, and it is listed under CFDA 93.243 (Substance Abuse and Mental Health Services - Projects of Regional and National Significance), which aligns with the national scope and capacity-building nature of PCSS.
From a policy and statutory standpoint, the program is authorized under Section 509 of the Public Health Service Act, as amended, and it directly supports the intent of DATA (including amendments made by the Office of National Drug Control Policy Reauthorization Act of 2006, Public Law 109-469). It also aligns with Healthy People 2010, focus area 26 on Substance Abuse, signaling the federal government’s emphasis at the time on expanding access to evidence-based treatment for substance use disorders. For applicants needing help accessing the full announcement, the notice provides a SAMHSA grants management contact (William Reyes) with phone and email information.
FY 2010 PCSS (Buprenorphine) Cooperative Agreement FAQs
1) What is the FY 2010 PCSS funding opportunity?
The FY 2010 Cooperative Agreement for the Physician Clinical Support System for the Treatment of Substance Use Disorders (PCSS) is a SAMHSA Center for Substance Abuse Treatment funding opportunity focused on strengthening a national clinical support network that helps physicians treat opioid dependence using FDA-approved buprenorphine products.
2) What is the main goal of PCSS?
The central goal is to enhance and further develop the existing DATA Physician Clinical Support System so that more clinicians, particularly those who do not specialize in addiction medicine, can confidently and competently provide office-based treatment for patients dependent on heroin or prescription opioids.
3) What types of opioid dependence treatment does PCSS support?
PCSS supports office-based opioid treatment using FDA-approved buprenorphine products for opioid dependence (including dependence involving heroin or prescription opioids).
4) Is this a direct service delivery grant?
No. This opportunity is described as part of SAMHSA's broader "infrastructure" portfolio. The emphasis is on building durable systems (such as mentoring, consultation, and expert guidance) that make effective prevention and treatment services easier to deliver and sustain, rather than simply paying for direct patient services.
5) What does it mean that this award is a cooperative agreement?
The opportunity is structured as a cooperative agreement, which typically indicates substantial federal involvement during the project period, rather than a hands-off grant.
6) What clinical support components are already in place in the existing PCSS infrastructure?
The existing national infrastructure referenced includes a large mentoring pool (over 70 mentors), five clinical experts, and a medical director. The cooperative agreement aims to expand and refine that capacity to reach more prescribers and improve consistency and quality of care.
7) Who is the intended audience for PCSS clinical support?
PCSS is designed primarily for clinicians who encounter opioid-dependent patients but may be less familiar with addiction treatment than dedicated addiction specialists. The target audience explicitly includes primary care physicians, pain specialists, psychiatrists, and other non-addiction medical practitioners.
8) Are addiction specialists included or excluded?
Addiction specialists are not excluded. They are encouraged to participate either as learners within the system or as mentors who support other physicians seeking to provide buprenorphine-based treatment.
9) What problem or need is this program trying to address?
The opportunity is intended to respond to field needs such as clinicians lacking experience with opioid dependence treatment. Applicants are expected to connect identified needs to an infrastructure strategy (for example, mentoring models, clinical consultation, and expert guidance) that increases national system capacity and supports better, more sustainable treatment services.
10) What kinds of strategies are applicants expected to propose?
Based on the announcement description, applicants are expected to propose infrastructure strategies such as mentoring models, clinical consultation, and expert guidance that expand and refine a national clinical support network for buprenorphine-based opioid dependence treatment.
11) Who is eligible to apply?
Eligibility is intentionally narrow and tied to the Drug Addiction Treatment Act of 2000 (DATA), as amended. Only national professional medical organizations authorized under DATA to conduct training for physicians seeking to prescribe and/or dispense buprenorphine for opioid addiction may apply.
12) Which organizations are specifically listed as eligible applicants?
The eligible organizations listed are:
- American Society of Addiction Medicine
- American Academy of Addiction Psychiatry
- American Medical Association
- American Osteopathic Association
- American Psychiatric Association
13) Can a consortium apply, or must it be a single organization?
Applications may be submitted by a single eligible organization or by a consortium of multiple eligible organizations.
14) If a consortium applies, what additional requirements apply?
If a consortium applies, one organization must serve as the legal applicant and be responsible for the award and compliance. The application must also include a signed written agreement that details the roles and responsibilities of each participating organization.
15) How many awards did SAMHSA anticipate making?
SAMHSA anticipated making one award, indicating this was intended as a single national award supporting a nationwide infrastructure effort.
16) What is the total amount of funding available?
The estimated total funding amount is $500,000.
17) What is the maximum award amount (ceiling)?
The award ceiling is $500,000.
18) Is there a minimum award amount (floor)?
No minimum amount is stated. The award floor is listed as $0.
19) Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
20) What are the key dates for this opportunity?
The opportunity was posted on July 1, 2009. The application deadline was September 17, 2009. The archive date was October 17, 2009.
21) What is the funding activity category?
The funding activity category is Health.
22) What is the CFDA number for this opportunity?
The opportunity is listed under CFDA 93.243, Substance Abuse and Mental Health Services - Projects of Regional and National Significance.
23) What federal authorities or policies does the program align with?
The program is authorized under Section 509 of the Public Health Service Act, as amended. It directly supports the intent of DATA (including amendments made by the Office of National Drug Control Policy Reauthorization Act of 2006, Public Law 109-469). It also aligns with Healthy People 2010, focus area 26 on Substance Abuse.
24) Who can be contacted for help accessing the full announcement?
The notice provides a SAMHSA grants management contact: William Reyes (phone and email are referenced in the notice) for applicants needing help accessing the full announcement.
Browse more opportunities from the same agency: Substance Abuse Mental Health Services Adminis.
Browse more opportunities from the same category: Health
Next opportunity: DFG/NEH Bilateral Digital Humanities Program Enriching Digital Collections
Previous opportunity: San Simon Watershed Assessment
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for TI 10 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (TI 10 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| CHILDRENS HEALTH INSURANCE PROGRAM REAUTHORIZATION ACT (CHIPRA) OUTREACH AND ENROLLMENT GRANTS CYCLE I Apply for HHS 2009 CMS CHIPRA 0008 Funding Number: HHS 2009 CMS CHIPRA 0008 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,000,000 |
| AHRQ Individual Awards for Postdoctoral Fellows (F32) Ruth L. Kirschstein National Research Service Awards (NRSA) Apply for PA 09 229 Funding Number: PA 09 229 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| AHRQ Developing Prospective Practice based Comparative Effectiveness Research Clinical Registries Orthopedic Devices, Drugs, and Procedures (P50) Apply for RFA HS 10 008 Funding Number: RFA HS 10 008 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01) Apply for PA 09 217 Funding Number: PA 09 217 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Proteomics in Auditory Developmental and Disease Processes (R01) Apply for PA 09 228 Funding Number: PA 09 228 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Oral Mucosal Vaccination against HIV Infection (R01) Apply for RFA DE 10 001 Funding Number: RFA DE 10 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Emergency Response (PHER) Apply for CDC RFA TP09 902 H1N109 Funding Number: CDC RFA TP09 902 H1N109 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Support for Implementation and Expansion of HIV Prevention, Care and Treatment Services at National Teaching and Referral Hospitals (NT RHs) As Centers of Excellence in the Republic of Kenya Under The President s Emergency Fund for AIDS Relief (PEPF Apply for CDC RFA PS10 1004 Funding Number: CDC RFA PS10 1004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Strengthening Health Outcomes through the Private Sector (SHOPS) Apply for M OAA GH POP 09 0709 Funding Number: M OAA GH POP 09 0709 Agency: Agency for International Development Category: Health Funding Amount: $200,000,000 |
| Grants to States for Loan Repayment Apply for HRSA 09 228 Funding Number: HRSA 09 228 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NHLBI Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD Fellows (F30) Apply for PA 09 232 Funding Number: PA 09 232 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Partnerships with Product Development Public Private Partnerships (R01) Apply for RFA AI 09 034 Funding Number: RFA AI 09 034 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of New Technologies Needed for Studying the Human Microbiome (R01) Apply for RFA RM 09 008 Funding Number: RFA RM 09 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of New Technologies Needed for Studying the Human Microbiome (R21) Apply for RFA RM 09 009 Funding Number: RFA RM 09 009 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiological MCH/SPH Institute Apply for HRSA 09 265 Funding Number: HRSA 09 265 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Short Term Research Education Program to Increase Diversity in Health Related Research (R25) Apply for RFA HL 10 013 Funding Number: RFA HL 10 013 Agency: National Institutes of Health Category: Health Funding Amount: $106,250 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R01) Apply for RFA HG 09 011 Funding Number: RFA HG 09 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R21) Apply for RFA HG 09 012 Funding Number: RFA HG 09 012 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (SBIR R43/R44) Apply for RFA HG 09 013 Funding Number: RFA HG 09 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Awards to Support Research on the Biology of Aging in Invertebrates (R01) Apply for RFA AG 10 004 Funding Number: RFA AG 10 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "TI 10 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.